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The human blood group A-specified 3-ar-N-acetyl- 
D-galactosaminyl-, B-specified 3iu-D-galactosyl- and 
H-specified 2-o-L-fucosyltransferases occur in soluble 
form in sera [l-6] and as membrane-bound enzymes 
in erythrocytes [I ,7-lo] from individuals with 
common ABO phenotypes. They are associated with 
two different genetic systems: the first two are 
related to the ABO locus and the third to the Hh 
locus. These activities have been also studied in 
unusual blood groups such as ‘Bombay’ phenotypes 
[7,8,11 ,121, A variants [9,13], B variants: B weak 
[14]; B, [ 10,14,15]; and cisAB [ 16-181. 
In this work, B variants from Ba, B, and Be, sub- 
groups [ 191 were investigated for A, B and H blood 
group glycosyltransferase activities using low molecu- 
lar weight acceptors or (and) 0 red cell conversion. 
Studies on N-acetylglucosamine$-D-galactosyItrans- 
ferase activity in the sera were included as controls 
of state of preservation. Moreover, when activities 
were not detected, attempts were made to concen- 
trate potential weak B-transferase. 
2. Materials and methods 
Our study is based on nine B variant samples 
belonging to seven families (Ba: Car, Pan, Sal; B,: 
Opa, Voi; BeI: Aba, Iss), the immunological and ther- 
modynamic properties of these variants were reported 
in [20-221. Sera were stored at -80°C for several 
months and at -20°C for a shorter time, red cells 
were kept frozen at -196°C until used. Erythrocyte 
membranes were prepared from fresh or stored red 
cells according to 123 1. The protein content of the 
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red cell membrane preparations was estimated by a 
modified Lowry’s method [24]. 
UDP-N-acetyl- [ I-r4C] galactosamine (47.2 mCi/mM) 
and UDP-[‘4C]galactose (283 mCi/mM) were pur- 
chased from the New England Nuclear Corp. They 
were used in 50% and 2% ethanolic solution, respec- 
tively. GDP-(‘“Clfucose (118 mCi~mM) was pur- 
chased from the Radiochemical Centre (Amersham) 
and used in 2% ethanolic solution. Unlabelled UDP- 
N-acetylgalactosamine was prepared according to 
125,261; UDP-galactose was purchased from Sigma 
Chemical Co. 2’-Fucosy~actose (2’FL: O-o-L-fuco- 
pyranosyl-(l -2)U~-~-galactopyranosyl~ 1-4)-D- 
glucopyranose) was extracted from human milk. 
Lacto-N-biose I (LNB I: OQ-D-galactopyranosyl- 
(l -3)N-acetyl-D-glucosamine) came from Sefochem 
and ~-acetylglucosamine from Sigma Chemical Co. 
Transferase assays in human sera: standard and 
extended conditions for A and B transferase assays 
have been described [5,13,18] as well as conversion 
of 0 red cells [ 181 and N-acetylglucosamine:&D- 
galactosyltransferase assays [9]. Incubations for 
H-transferase activity contained in 55 1.11, the follow- 
ing: 25 ~1 serum, 0.9 pmol LNB I, 0.9 nmol GDP- 
[‘4C]fucose (1.9 X 10’ cpm), 0.6 pmol MgC12, 
2.5 umol Tris-HCl buffer (pH 7.2), 1 pmol ATP and 
1 pmol NaN,; incubated for 72 h at 37°C. 
Transferase assays in erythrocyte membranes: for 
all these experiments, 250 yg erythrocyte membrane 
protein were used as enzymic source. A-transferase 
activity was estimated according to [9]. B-transferase 
assays were carried out in 150 ~1 and contained: 
erythrocyte membranes, 0.4 pmol 2’FL, 0.6 nmol 
UDP-[‘4C)GaI (3 X 10’ cpm), 1.25 gmol MnCl*, 
6.0 pmol Hepes buffer (pH 6.5) and 0.3% (v/v) 
Triton X-100. 
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Reaction products were isolated and estimated as 
in [7,9,18] except for the fl-galactosyltransferase 
product which was isolated after electrophoresis by 
descending chromatography in butanol/ethanol/water 
solvent (10/l/2, by vol.) for 72 h (RGal = 0.52). 
Attempts to concentrate B-transferase activity: 
proteins were precipited at 60% of an ammonium sul- 
fate saturated solution, desalted by filtration on a 
Sephadex G-50 column (medium) then concentrated, 
in batch, using Sephadex G-25 (coarse). All proce- 
dures were carried out at 4°C. Tests were performed 
in the extended conditions above. 
3. Results and discussion 
Human blood group A, B and H-gene specified 
glucosyltransferases were investigated in sera and 
erythrocyte membranes from nine B variants belong- 
ing to seven families using low molecular weight 
acceptors: 2’fucosyllactose, for A and B, lacto-IV- 
biose I for H. Moreover, conversion assays of 0 red 
cells into A and B reactive cells were used. Sera and 
red cell membranes from common groups B (BI and 
B,, [SJ), A,, AZ and 0 were included as controls. 
The 3a-D-galactosyltransferase activity was clearly 
detected only in B3 and normal B sera using 2’FL as 
well as 0 red cells as substrates (table 1). Other sera 
from B, and BeI donors were devoid of B-transferase 
activity even when they were tested in extended condi- 
tions. As no decrease for 2_ac-L-fucosyltransferase and 
4&D-galactosyltransferase was observed the state of 
preservation seemed not to be involved in these 
results. As described in section 2, attempts were made 
to concentrate potential B-transferase activity. The 
coefficient of concentration obtained was -2-4. 
Except for B3 and normal B sera, all the B experi- 
ments were negative (table 2). When purified B-tetra- 
[14C]saccharide (I.25 X 10’ cpm) was incubated in 
extended conditions, without the substrates, with the 
different samples studied here, no release of galactose 
was observed. Moreover, mixtures of normal B and B 
variant sera (1 /I, v/v), in standard conditions, trans- 
ferred the same quantity of [14C]galactose from 
UDP-[14C]galactose to 2’FL as the mixture used as 
control: normal B and 0 sera (l/l, v/v). These exper- 
iments allowed the exclusion of glycolytic activity 
towards hypothetically formed B-product and an 
inhibition effect towards potential B-transferase in 
the B variant samples studied. 
The erythrocyte membrane preparations from all 
the B variants do not contain detectable 3_cr-D-galac- 
tosyltransferase xcept for B, and B,, samples even 
when 3-cu-N-acetylgalactosaminyl- for AB variants and 
2ci-L-fucosyltransferases were clearly demonstrated. 
If transferase activities of RBC membranes reflect 
those of hematopoetic tissue, this could suggest hat 
the B-gene was not normally expressed in hemato- 
poetic tissue, due perhaps to the action of a modify- 
ing gene in this cellular line, as described for B, [lo] 
and A, [ 131 phenotypes. Although the contribution 
of erythroblasts to the transferase activity in the 
Table 2 
The 3wDgalactosyltransferase activity in sera from B and B, donors in different experimental 
conditions, expressed as pmol product formed 
3*-DGalactosyltransferase activity on 2’FL On 0 RBC 
Standard Extended Assay Standard conditions Assay cont. 
conditions conditions cont. 
Score Titre Score Titre 
B II 26.3 f 3.0 (21) 138 236 83 1024 95 1024 
BI 11.2 +_ 2.7 (107) 53 150 71 256 96 1024 
B, CAR. 8.7 n.t. 96 53 64 83 512 
B, PAN. 10.0 32 102 80 1024 91 1024 
Bx, Be1 
samples 0 0 0 0 - 0 - 
The conditions are in section 2. Results are expressed as pmol B-product formed on 2’FL or as scores 
and titres of haemagglutination using anti-B(A) immune serum (titre 4096 on B cells) 
27 
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serum was estimated from chimera studies at -20% 
[3,13], B-gene specified glycosyltransferase in Bs sera 
is as active as in normal B, taking into account the 
individual variations. In any case, if this mechanism 
fits perfectly with the B, and A, phenotypes, it 
does not reflect the high capacity of B3 erythrocytes 
to be agglutinated. More likely, the absence of 
B-transferase activity in B3 RBC membrane assays 
could result from an altered enzyme, more labile 
than that of normal B, which could have some activ- 
ity in intracellular medium. 
As for the other B-variants, B, and Be,, undetect- 
able B-transferase activity in sera as well as in RBC 
membranes could arise from qualitatively or quanti- 
tatively modified enzyme. An unexcreted transferase 
or some regulatory or modifying functions could be 
involved too. Meanwhile, in all AB variants studied 
here and in [ 151, A-transferase activity remained 
unchanged. On the other hand, from immunological 
homology studies on ABO glycosyltransferases, it was 
proved in [27] that the genes governing blood group 
expression should be truly allelic. These data are not 
consistent with regulatory control in ABO in blood 
group expression; only one case has been described 
[28] where perhaps a modifying gene acted on A and 
B blood group expression of two related individuals 
(A/O and B/O). Unfortunately glycosyltransferase 
activities were not studied. Lastly, as shown in [29] 
for one case of cisAB inheritance, an unequal cross- 
ing over producing a chromosome with alleles for 0 
and B enzymes could also be a possible explanation 
for some B variants. 
Thermodynamic and immunologic studies 
[20-221 and these enzymic results seem to demon- 
strate that B variants are homogeneous in the same 
kindred but are heterogeneous from one family to 
another. It is likely that the different B variants do 
not arise from a single mechanism but are the expres- 
sion of different and convergent phenomena. 
References 
[ 1 ] Kim, Y. S., Perdomo, J., Bella, A. and Nordberg, J. 
(1971)Proc. Natl. Acad. Sci. USA 68,1753-1756. 
[2] Sawicka, T. (1971) FEBS Lett. 16,346-348. 
[ 31 Schachter, H., Michaels, M. A., Crookston, M. C., 
Tilley, C. A. and Crookston, J. H. (1971) Biochem. 
Biophys. Res.Commun.45,1011-1018. 
[4] Schenkel-Brunner, H., Chester, A. and Watkins, W. M. 
(1972) Eur. J. Biochem. 30,269-277. 
[5] Badet, J., Ropars, C., Cartron, J. P., Doinel, C. and 
Salmon, C. (1976) VOX Sang. 30,105-l 10. 
[6] Pacuszka. T. and Koicielak. J. (1976) Eur. J. Biochem. 
64,499-;06. 
I71 
[81 
I91 
[lOI 
[Ill 
[I21 
1131 
1141 
[151 
[I61 
I171 
1181 
[I91 
PO1 
I211 
[=I 
i231 
~41 
1251 
[261 
v71 
WI 
v91 
Mulet, C., Cartron, J. P., Badet, J. and Salmon, C. 
(1977) FEBS Lett. 84,74-78. 
Mulet, C., Cartron, J. P., Lopez, M. and Salmon, C. 
(1978) FEBS Lett. 90,233-238. 
Cartron, J. P., Badet, J., Mulet, C. and Salmon, C. 
(1978) J. Immunogenet. 5,107-116. 
Koscielak, J., Pacuszka, T. and Dzierikowa-Borodej, W. 
(1976) VOX Sang. 30,58-67. 
Race, C. and Watkins, W. M. (1972) FEBS Lett. 27, 
125-130. 
Race, C. and Watkins, W. M. (1972) VOX Sang. 23, 
385-401. 
Cartron, J. P., Gerbal, A., Badet, J., Ropars, C. and 
Salmon,C. (1975) Vox Sang. 28,347-365. 
Kogure, T. and Furukawa, K. (1976) J. Immunogenet. 
3,147-154. 
Simmons, A. and Twaitt, J. (1975) Transfusion 15, 
359-362. 
Kogure, T. (1975) VOX Sang. 29,51-58. 
Pacuszka, T., Koscielak, J., Seyfried, H. and Waleska, I. 
(1975) VOX Sang. 29,292-300. 
Badet, J., Ropars, C. and Salmon, C. (1978) J. Immuno- 
genet. 5,221-231. 
Salmon, C. and Cartron, J. P. (1977) in: CRC Hand- 
book Series in: Clinical Laboratory Science, Section D: 
Blood Banking, pp. 87-91. 
Salmon, C., Liberge, G., Gerbal, A. and Lopez, M. 
(1974) Biomedicine 21,465-470. 
Lopez M., Bouguerra, A., Lemeud, J., Badet, J. and 
Salmon,C. (1974) VOX Sang. 27,243-253. 
Salmon, C. (1976) Rev. Fr. Transfus. Hematol. XIX, 
89-104. 
Dodge, J. T., Mitchell, C. and Hawahan, D. J. (1963) 
Arch. Biochem. Biophys. 100,119-130. 
Geiger, P. J. and Bessman, S. P. (1972) Anal. Biochem. 
49,467-473. 
Carlson, D. M., Swanson, A. L. and Roseman, S. (1964) 
Biochemistry 3,402-405. 
Furusawa, K., Sekine, M. and Hata, T. (1976) J. Chem. 
Sot. Perkin I, 1711-1716. 
Yoshida, A., Yamaguchi, Y. F. and Dave, V. (1979) 
Blood 54,344-350. 
Rubinstein, P., Allen, F. H. and Rosenfield, R. E. (1973) 
VOX Sang. 25,377-381. 
Yoshida, A., Yamaguchi, H. and Okubo, Y. (1980) Am. 
J. Hum. Genet. 32,332-338. 
28 
